Get the Weekly Intelligence Brief — top committee picks every Sunday.

HSIC vs TVTX

Henry Schein vs Travere Therapeutics, Inc. — AI-powered side-by-side comparison
HSIC
Henry Schein
67
Buy
VS
TVTX
Travere Therapeutics, Inc.
62
Buy
MetricHSICTVTX
AI Score 67 62
Price $89.16 $60.25
P/E Ratio 25.77× -133.80×
ROE 12.3% -22.2%
Revenue Growth YoY
Gross Margin 30.3% 94.4%
Debt / Equity 1.21× 25.16×
Dividend Yield 0.0% 0.0%
RSI (14) 59.4 59.0
Beta 0.808 1.042
Expected Upside +0.8%

AI Committee View

Current Innellis committee reasoning for HSIC versus TVTX.
HSIC leads by 5 points.

HSIC scores 67/100 (Buy) versus TVTX at 62/100 (Buy).

HSIC Committee View
75% agreement
4 analysts

The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.

Bull Case
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
TVTX Committee View
75% agreement
4 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 17.2% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
  • Bollinger bandwidth of 17.2% signals elevated volatility — Risk
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
HSIC Full Analysis TVTX Full Analysis